DXCM currently has a PEG ratio reading of 0.45 as of Aug 21, 2026. Dividing the 35.65 PE ratio by the 78.6% earnings growth rate yields this valuation metric. When compared to the trailing four-quarter average of 1.94, DXCM's PEG ratio shows a 77% decrease.
A eight years lookback shows an average PEG ratio of 2.17 for Dexcom. Compared to historical data, DXCM's 0.45 PEG ratio represents a decrease of 79%. The eight years high occurred in the Dec 2024 quarter at 12.39, reflecting maximum valuation relative to growth. The minimum was hit in the Dec 2020 quarter at 0.15, indicating optimal value relative to growth during that period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.67 | 31.01 | 46.6% |
| 2024 | 12.39 | 53.27 | 4.3% |
| 2023 | 1.5 | 88.64 | 59.1% |
| 2022 | 2.25 | 128.68 | 57.1% |
| 2021 | N/A | 239.71 | -61.6% |
| 2020 | 0.15 | 63.31 | 421.4% |
| 2019 | 1.1 | 195.3 | 177.8% |
| 2018 | N/A | N/A | -140% |
| 2017 | N/A | N/A | 25% |
| 2016 | N/A | N/A | -11.1% |
| 2015 | N/A | N/A | -125% |
| 2014 | N/A | N/A | 27.3% |
| 2013 | N/A | N/A | 45% |
| 2012 | N/A | N/A | -17.6% |
| 2011 | N/A | N/A | 29.2% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Jun 2026 | 0.33 | 26 | 78.6% |
| Mar 2026 | 0.34 | 26.17 | 77.8% |
| Dec 2025 | 0.67 | 31.01 | 46.6% |
| Sep 2025 | 6.42 | 36.57 | 5.7% |
| Jun 2025 | N/A | 60.2 | -15.2% |
| Mar 2025 | N/A | 50.59 | -18.2% |
| Dec 2024 | 12.39 | 53.27 | 4.3% |
| Sep 2024 | 0.5 | 38.53 | 77.6% |
| Jun 2024 | 0.79 | 66.3 | 83.9% |
| Mar 2024 | 0.72 | 84.06 | 117.1% |
| Dec 2023 | 1.5 | 88.64 | 59.1% |
| Sep 2023 | 1.71 | 95.2 | 55.6% |
| Jun 2023 | 2.51 | 138.18 | 55% |
| Mar 2023 | 11.41 | 152.87 | 13.4% |
| Dec 2022 | 2.25 | 128.68 | 57.1% |
When comparing to historical values, DXCM's PEG ratio is below the 3, 5 and 10-year averages.
With a PEG of 0.45, DXCM stands above the industry average but below the Healthcare sector average. Compared to its Healthcare sector average of 0.61, Dexcom's PEG is 26% lower.
DXCM has a PEG ratio below that of peer stocks MDT and WST.
DXCM's Aug 21, 2026 PEG ratio comes in at 0.45.
DXCM's 3-year PEG ratio average stands at 2.54.
DXCM's 5-year PEG ratio average stands at 3.0.
In the last eight years, DXCM's peak PEG ratio of 12.39 was recorded in the Dec 2024 quarter.
Compared to the 8-year average, DXCM's PEG ratio is 79% lower.
At 0.45, DXCM's PEG ratio suggests the stock may be attractively priced given its growth rate.
PEG equals PE divided by EPS growth (YoY TTM). As of Aug 21, 2026, Dexcom has a P/E ratio of 35.65. Earnings grew at 78.6% over the TTM period ending Jun 2026. Applying the formula, this produces a price to earnings growth ratio of 0.45. PEG RATIO(0.45) = PE RATIO(35.65) / EPS GROWTH(78.6%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.